Second GeneTACTM Development Candidate, DT-168, Selected for the Treatment of Fuchs Endothelial Corneal Dystrophy Administered as an Eye Drop; IND Expected in 2023
Advancing Myotonic Dystrophy Type-1 GeneTACTMLead Molecules; IND Expected in 2024
Conference Call to be Held Today at 4:30pm ET
CARLSBAD, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today reported progress across its portfolio of novel GeneTAC™ small molecules. Today’s updates include initial results on DT-216 from the company’s single-ascending dose (SAD) Phase 1 clinical trial in patients with Friedreich ataxia (FA). The results show that DT-216 was generally well-tolerated and able to overcome the frataxin (FXN) transcription impairment that causes FA, with a greater than two-fold increase in FXN mRNA in the cohort with the highest response. These data support the continued advancement of DT-216 in the ongoing multiple-ascending dose (MAD) Phase 1 trial and the anticipated Phase 2 clinical trial in FA patients, which is on track to begin in 2023.
Read the Full article here
